HOOKIPA Pharma Inc.

HOOK11 Dec 2024
Healthcare
$2.39
-0.02 (-1.66%)
Lowest Today
$2.37
Highest Today
$2.4
Today’s Open
$2.39
Prev. Close
$2.41
52 Week High
$11.3
52 Week Low
$2.08
To Invest in HOOKIPA Pharma Inc.

HOOKIPA Pharma Inc.

Healthcare
HOOK11 Dec 2024
-0.02 (-1.66%)
1M
3M
6M
1Y
5Y
Low
$2.37
Day’s Range
High
$2.4
2.37
52 Week Low
$2.08
52-Week Range
52 Week High
$11.3
2.08
1 Day
-
1 Week
+4.09%
1 month return
-32.08%
3 month return
-51.8%
6 month return
+219.85%
1 Year return
+290.16%
3 Years return
-9.44%
5 Years return
-66.22%
10 Years return
-
Institutional Holdings
Baker Bros Advisors LP
6.74
EcoR1 Capital, LLC
4.74
Knoll Capital Management LP
4.58
FMR Inc
2.83
Vanguard Group Inc
1.77
Vanguard Total Stock Mkt Idx Inv
1.17
Redmile Group, LLC
0.88

Market Status

Fundamentals
Market Cap
30.62 mln
PB Ratio
0.42
PE Ratio
0
Enterprise Value
-26.67 mln
Total Assets
161.34 mln
Volume

Company Financials

Fund house & investment objective

Company Information
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial. The company's preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Organisation
HOOKIPA Pharma Inc.
Employees
151
Industry
Biotechnology
CEO
Dr. Malte  Peters M.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities